Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00107458 · ClinicalTrials.gov registry record · Phase 1

Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

A Phase 1 study, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT00107458 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00107458, a Phase 1 study, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of valproic acid in treating patients with recurrent or refractory solid tumors or CNS tumors.

Interventions

  • DRUG valproic acid

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2005-05
Est. Completion 2012-03
Phase Phase 1

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT00107458

The ClinicalTrials.gov registry entry for NCT00107458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which valproic acid is the first listed.

NCT00107458 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00107458 about?

NCT00107458 is a clinical study titled "Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors". RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow to the tumor. PURPOSE: T...

What is the current status of trial NCT00107458?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2005-05. Estimated completion is 2012-03.

What interventions are being tested in trial NCT00107458?

The interventions under investigation include: valproic acid (DRUG).

Who is sponsoring clinical trial NCT00107458?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.